Finasteride Side-Effect Reports from Real Users
Finasteride is an oral 5-alpha reductase inhibitor sold under the brand name Propecia at a 1 mg daily dose for male pattern hair loss, and under the brand name Proscar at a 5 mg daily dose for benign prostatic hyperplasia (BPH). Generic finasteride is available at both strengths. This article covers the 1 mg hair-loss dose unless otherwise noted, because that is the dose most reflected in the online reviews and forum discussions people search for.
This article does not diagnose or recommend a dose. It is pending qualified medical review.
The direct answer
Reddit threads, Drugs.com reviews, and clinical trials are measuring different things, and neither one alone answers "how likely is this to happen to me." Randomized trials, using structured questionnaires in blinded settings, consistently find that sexual side effects occur in a low single-digit percentage of men on 1 mg finasteride, only modestly above the rate in men taking placebo, and that most reported side effects resolve after stopping the drug. Online reviews and forums are unblinded, self-selected, and skew toward people who had a bad experience, because people who tolerate a drug without incident rarely write about it. A smaller, harder-to-quantify group reports symptoms that persist after stopping finasteride, a pattern sometimes called post-finasteride syndrome; it is not a recognized diagnosis in DSM-5 or ICD-11, but the FDA-approved label has since 2012 acknowledged post-marketing reports of libido, ejaculation, and orgasm disorders that continued after the drug was stopped.
What clinical trials show, and what they don't
The pivotal trials supporting the 1 mg indication followed men with androgenetic alopecia for one to five years, comparing finasteride against placebo using structured sexual-function questionnaires. Across that literature, sexual side effects (decreased libido, erectile difficulty, reduced ejaculate volume) were reported somewhat more often in the finasteride arm than the placebo arm in the first year, with the gap between groups narrowing in later years of continued use. Exact percentages vary by trial and by which endpoints are counted, and readers should treat any single precise figure (for example, "1.3% versus 3.8%") as needing verification against the current trial publication or the FDA label rather than as a fixed number.
The Prostate Cancer Prevention Trial, which used the 5 mg BPH dose in an older population with a much higher baseline rate of sexual dysfunction, found a real but modest absolute increase in sexual dysfunction with finasteride compared to placebo over several years of follow-up. Dose matters here: 5 mg is five times the hair-loss dose, and the trial population was older and had higher starting rates of sexual dysfunction than typical hair-loss patients, so its absolute numbers do not transfer directly to a 1 mg hair-loss user.
A separate line of evidence comes from observational research on men who sought medical care specifically for sexual dysfunction while using a 5-alpha reductase inhibitor. One such study found that a subset of these men described symptoms persisting after stopping the drug, reinforcing that persistent symptoms are a real clinical phenomenon reported in a minority of users, even though the study cannot establish how common they are in the overall treated population (Corona et al., 2012).
Systematic reviews pooling multiple RCTs have generally found a statistically significant but small relative increase in sexual dysfunction risk with finasteride versus placebo, with a low absolute risk difference. Specific pooled numbers (relative risk, number needed to harm) circulate widely online; treat any single cited figure as unverified until checked against the current published meta-analysis, since this is exactly the kind of precise number that gets miscited or copied incorrectly between sources.
What online forums and review sites actually capture
Reddit communities such as r/tressless discuss finasteride experiences across a wide range, from brief posts reporting good results with no side effects to long, detailed threads describing brain fog, mood changes, or sexual side effects. Subreddits organized specifically around suspected harm (for example, communities dedicated to post-finasteride symptoms) are, by design, self-selected populations of people who believe they were harmed. They are a useful window into what affected users experience and how they describe it, but they cannot be used to estimate how common that experience is among all finasteride users.
Aggregated review sites like Drugs.com show a similarly bimodal pattern: strong positive ratings for hair regrowth sitting next to strongly negative ratings citing sexual or mood side effects. This pattern is consistent with what is generally understood about online drug reviews across many medications: people who have an uneventful experience are less likely to write a review than people who had a problem, which skews the visible sample toward negative reports regardless of the drug's actual population-level side-effect rate. The exact magnitude of that skew for finasteride specifically has not been rigorously quantified in the sources reviewed for this article, so any specific multiplier (such as "reviews overrepresent negative outcomes by 2 to 3 times") should be treated as an approximation, not a precise, sourced figure.
The nocebo effect is documented, but it does not explain everything
A recognized phenomenon in this area is the nocebo effect: telling patients about a drug's possible side effects measurably increases how often they report those side effects, even when the drug and dose are identical. A randomized study in men taking finasteride 5 mg for BPH found that men who were informed in advance about possible sexual side effects reported them considerably more often than men who were not informed, despite receiving the same treatment. This demonstrates that expectation shapes symptom reporting, which matters for interpreting forum posts written by people who went looking for information about side effects before or during treatment.
It does not follow that all reported side effects are attributable to expectation alone. Researchers who study persistent post-finasteride symptoms have argued that nocebo effects are real and measurable but do not account for every case, particularly among men who report objectively measurable hormonal or neurological changes that persist well after stopping the drug. Both things can be true at once: expectation inflates self-reported rates in the aggregate, and a genuine, smaller subgroup experiences something that persists regardless of what they expected.
Post-finasteride syndrome: what is established and what is not
Post-finasteride syndrome (PFS) is not a formally recognized diagnosis in DSM-5 or ICD-11. What is established is narrower: the FDA-approved label for finasteride has included language since 2012 describing post-marketing reports of libido, ejaculation, and orgasm disorders that continued after men stopped the drug. A label update based on adverse event reports is evidence that regulators found the reports credible enough to disclose, not proof of a specific incidence rate or a defined causal mechanism.
More recent pharmacovigilance research has examined real-world adverse event reports submitted to the FDA's Adverse Event Reporting System (FAERS), including a 2025 analysis specifically evaluating suicidality signals associated with finasteride (Wang et al., 2025). FAERS analyses like this one can flag a disproportionate reporting signal that regulators and researchers should investigate further, but FAERS data comes with the same core limitation as forum posts: it is unblinded, voluntarily submitted, and cannot establish that finasteride caused any individual reported event. It is one step more structured than a Reddit post, and several steps less rigorous than a controlled trial.
Smaller mechanistic studies have proposed that finasteride's inhibition of 5-alpha reductase could alter neurosteroid levels (including allopregnanolone, a downstream metabolite that affects GABA-A receptor function), which is biologically plausible as an explanation for mood and cognitive symptoms in a subset of users. This remains an area of active investigation rather than an established causal pathway, and depression and sexual dysfunction are both common in the general adult male population independent of any medication, which makes attributing any individual case to finasteride difficult without a well-designed prospective study.
An evidence-review framework for weighing a side-effect report
Not every report of a finasteride side effect carries the same evidentiary weight, and not every tier of evidence answers the same question. This framework separates what each source of information can and cannot tell a prospective or current user, and what the reasonable next step is at each tier.
| Evidence tier | What it can tell you | What it cannot tell you | Reasonable next step |
|---|---|---|---|
| Single Reddit or Drugs.com post | That this experience happened to at least one person, and roughly how it was described | How common it is, whether the drug caused it, or whether it will happen to you | Note the symptom pattern; do not use it to estimate your personal risk |
| Forum or subreddit sentiment overall | The range and texture of user-described experiences, both positive and negative | Population-level incidence, because posting behavior is skewed toward people with problems | Use for awareness of possible symptoms to watch for, not for probability |
| FAERS or other spontaneous adverse-event data | Whether a symptom is being reported at a disproportionate rate worth regulatory or research attention | Causation for any individual case; reports are voluntary and unverified | Take seriously as a signal; discuss with a prescriber if the symptom matches your experience |
| Observational studies of patients seeking care for sexual dysfunction | That persistent symptoms occur in at least some treated patients, described in clinical detail | The overall incidence in the general treated population, since these studies enroll patients who already have a complaint | Support for taking a persistent complaint seriously, not for estimating your odds beforehand |
| Randomized controlled trials with placebo arms | The closest available estimate of how much more often a side effect occurs with the drug than without it | Rare or highly delayed effects that a trial of limited size and duration is not powered to detect | Use trial-range estimates as your working baseline, checked against the current FDA label |
The decision this framework points to: use trial data and the FDA label to set your baseline expectation before starting, use FAERS and observational reports to know what symptom pattern would justify follow-up, and use forum and review-site reports only to understand how affected users describe their experience, never to estimate your own probability of being affected.
What this means in practice
Before starting, a reasonable conversation with a prescriber covers baseline sexual function, mental health history, and personal risk tolerance, set against realistic trial-based probabilities rather than worst-case forum stories. Monitoring in the first three to six months makes sense, since that is the window in which most side effects that occur tend to appear; a simple personal log of libido, erectile function, and mood kept before starting and at intervals afterward is less vulnerable to recall bias than relying on memory alone.
If side effects appear, discontinuation is the standard first response, and available trial data suggests most sexual side effects resolve after stopping. For anyone whose symptoms persist for a meaningful period after stopping the drug, referral to an endocrinologist for hormonal evaluation (total and free testosterone, estradiol, DHT, prolactin) is a reasonable next step, and this should not be dismissed as purely psychological without evaluation. Anyone experiencing suicidal thoughts or significant new depression while on or after finasteride should treat that as urgent and seek care immediately rather than waiting to see if it resolves.
What is established, what is plausible, and what is not established
Established: finasteride 1 mg reduces hair loss progression in RCTs; the FDA label acknowledges post-marketing reports of persistent sexual side effects after discontinuation; nocebo effects measurably influence self-reported side-effect rates in at least one randomized disclosure study.
Plausible but unproven: that altered neurosteroid signaling explains persistent mood and cognitive symptoms in a subset of users; that FAERS-detected suicidality signals reflect a causal drug effect rather than reporting bias or confounding by underlying depression.
Not established: the true population-level incidence of persistent post-finasteride symptoms; a validated diagnostic definition of post-finasteride syndrome; that online review or forum sentiment reflects the actual proportion of users affected.
Frequently asked questions
Frequently asked questions
How common are finasteride sexual side effects really?
Is post-finasteride syndrome a real diagnosis?
Do finasteride side effects go away after stopping?
Does the nocebo effect explain finasteride side effects?
Are Reddit and Drugs.com reviews reliable for estimating my risk?
Should I get blood work before starting finasteride?
What should I do if side effects persist after stopping finasteride?
References
- Corona G, et al. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. 2012. https://pubmed.ncbi.nlm.nih.gov/22777612/
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports. 2025. https://pubmed.ncbi.nlm.nih.gov/40732247/
Additional claims in this article reference the FDA-approved finasteride label and published randomized trials and meta-analyses described in general terms. Readers and reviewing clinicians should verify any specific percentage, relative risk, or trial citation against the current FDA label (accessible via Drugs@FDA on fda.gov) and the primary published literature before it is presented to patients as a precise figure.